FDAnews Drug Daily Bulletin

FDA Accepts Exelixis Treatment for Priority Review

Aug. 1, 2012
A A
Drugmaker Exelixis said the Food and Drug Administration has accepted its potential thyroid cancer treatment, carbozantinib, for priority review.
San Francisco Chronicle